Jeff Yass’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-10,900
| Closed | -$51K | – | 14697 |
|
|
2021
Q4 | $51K | Sell |
10,900
-7,100
| -39% | -$29.6K | ﹤0.01% | 12535 |
|
|
2021
Q3 | $72K | Sell |
18,000
-4,300
| -19% | -$17.1K | ﹤0.01% | 12216 |
|
|
2021
Q2 | $95K | Sell |
22,300
-20,800
| -48% | -$89.1K | ﹤0.01% | 12120 |
|
|
2021
Q1 | $183K | Buy |
43,100
+18,100
| +72% | +$99.7K | ﹤0.01% | 11500 |
|
|
2020
Q4 | $97K | Sell |
25,000
-15,900
| -39% | -$67.9K | ﹤0.01% | 10509 |
|
|
2020
Q3 | $165K | Buy |
40,900
+18,800
| +85% | +$77.9K | ﹤0.01% | 9617 |
|
|
2020
Q2 | $94K | Sell |
22,100
-10,100
| -31% | -$61.5K | ﹤0.01% | 9531 |
|
|
2020
Q1 | $135K | Buy |
32,200
+2,500
| +8% | +$15.8K | ﹤0.01% | 9089 |
|
|
2019
Q4 | $117K | Sell |
29,700
-17,800
| -37% | -$105K | ﹤0.01% | 9073 |
|
|
2019
Q3 | $418K | Sell |
47,500
-72,600
| -60% | -$686K | ﹤0.01% | 7669 |
|
|
2019
Q2 | $1.11M | Buy |
120,100
+52,900
| +79% | +$399K | ﹤0.01% | 5407 |
|
|
2019
Q1 | $432K | Buy |
67,200
+49,700
| +284% | +$324K | ﹤0.01% | 6551 |
|
|
2018
Q4 | $165K | Sell |
17,500
-14,800
| -46% | -$223K | ﹤0.01% | 7913 |
|
|
2018
Q3 | $650K | Buy |
32,300
+2,600
| +9% | +$68K | ﹤0.01% | 6065 |
|
|
2018
Q2 | $866K | Sell |
29,700
-109,600
| -79% | -$3.38M | ﹤0.01% | 5662 |
|
|
2018
Q1 | $4.15M | Sell |
139,300
-65,700
| -32% | -$2.12M | ﹤0.01% | 2777 |
|
|
2017
Q4 | $6.6M | Sell |
205,000
-610,200
| -75% | -$19.9M | ﹤0.01% | 2224 |
|
|
2017
Q3 | $28.4M | Buy |
815,200
+764,700
| +1,514% | +$24.6M | 0.01% | 983 |
|
|
2017
Q2 | $1.5M | Sell |
50,500
-20,900
| -29% | -$599K | ﹤0.01% | 4428 |
|
|
2017
Q1 | $2.13M | Buy |
71,400
+15,000
| +27% | +$383K | ﹤0.01% | 3604 |
|
|
2016
Q4 | $989K | Buy |
56,400
+32,800
| +139% | +$629K | ﹤0.01% | 5563 |
|
|
2016
Q3 | $561K | Sell |
23,600
-19,400
| -45% | -$366K | ﹤0.01% | 5864 |
|
|
2016
Q2 | $688K | Buy |
43,000
+15,100
| +54% | +$271K | ﹤0.01% | 5560 |
|
|
2016
Q1 | $583K | Buy |
27,900
+6,600
| +31% | +$118K | ﹤0.01% | 6135 |
|
|
2015
Q4 | $575K | Sell |
21,300
-33,000
| -61% | -$900K | ﹤0.01% | 6503 |
|
|
2015
Q3 | $1.51M | Buy |
54,300
+17,900
| +49% | +$564K | ﹤0.01% | 4861 |
|
|
2015
Q2 | $892K | Buy |
36,400
+13,300
| +58% | +$274K | ﹤0.01% | 6460 |
|
|
2015
Q1 | $423K | Buy |
+23,100
| New | +$468K | ﹤0.01% | 7398 |
|
Jeff Yass's LJPC Position: Q3 2022 in Review
Jeff Yass sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 22,193 shares — an estimated $71K sold.
Jeff Yass first reported a position in LJPC in Q1 2015 and held it in 23 quarters. The position peaked at $7.13M in Q3 2017. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- Jeff Yass reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- Jeff Yass sold 22,193 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $71K.
- Jeff Yass first reported a position in La Jolla Pharmaceutical Company in Q1 2015 and held it in 23 quarters.
- Jeff Yass's La Jolla Pharmaceutical Company position peaked at $7.13M in Q3 2017.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.